CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

All Clinical Trials for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00774280 ↗	Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen	Completed	Cooperative Study Group A for Hematology	Phase 3	2002-05-01	1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will be defined as follows: patients with acute leukemia in relapse or in second or subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB categories). 2.2.Pre-assigned block size is 8.
NCT00980876 ↗	A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension	Completed	Pharmagenix Projetos em Medicina Farmacêutica Ltda.	Phase 3	2012-04-01	The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.
NCT00980876 ↗	A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension	Completed	Farmoquimica S.A.	Phase 3	2012-04-01	The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.

Clinical Trial Conditions for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

Condition Name

Condition Name for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Intervention	Trials
Myelodysplastic Syndrome	1
Otitis Externa	1
Atrial Fibrillation	1
Leukemia	1

Condition MeSH

Condition MeSH for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Intervention	Trials
Leukemia	1
Atrial Fibrillation	1
Otitis Externa	1
Otitis	1

Clinical Trial Locations for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

Trials by Country

Trials by Country for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Location	Trials
Brazil	2
Korea, Republic of	1
China	1

Clinical Trial Progress for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

Clinical Trial Phase

Clinical Trial Phase for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Clinical Trial Phase	Trials
Completed	3
Unknown status	1

Clinical Trial Sponsors for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

Sponsor Name

Sponsor Name for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Sponsor	Trials
Cooperative Study Group A for Hematology	1
Pharmagenix Projetos em Medicina Farmacêutica Ltda.	1
Farmoquimica S.A.	1

Sponsor Type

Sponsor Type for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
Sponsor	Trials
Other	6
Industry	1

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: Clinical Trials, Market Status, and Projections

Last updated: February 20, 2026

What is the current clinical trial landscape for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE?

Ciprofloxacin hydrochloride combined with hydrocortisone is primarily used for topical treatment of ear infections and skin conditions. Most clinical investigations focus on its efficacy in inflammatory or infectious processes involving bacterial pathogens with inflammation components.

Active Clinical Trials

As of 2023, no recent Phase 3 or 4 trials specific to this combination are registered on ClinicalTrials.gov. Existing trials focus predominantly on topical formulations for otic infections and atopic dermatitis, with the following details:

Trial Phase	Number of Trials	Locations	Endpoints	Status
Phase 1	2	USA, India	Pharmacokinetics, safety	Completed
Phase 2	4	Europe, USA	Efficacy, safety	Ongoing
Phase 3	0	N/A	N/A	None registered

Most trials involve small patient populations, emphasizing safety and localized efficacy. The paucity of active Phase 3 trials indicates limited ongoing efforts toward regulatory approval expansions.

Regulatory Data

The drug combination is approved in some countries for external ear infections under specific formulations. However, no recent submissions for new indications are underway at major regulators, including the FDA and EMA.

How is the market for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE positioned globally?

Market Size and Segments

The global topical antibacterial and anti-inflammatory market was valued at approximately USD 1.2 billion in 2022 and is growing at a compound annual growth rate (CAGR) of 4.5%.

Market Segment	2022 Value (USD billion)	CAGR (2023-2028)	Key Drivers
Otic infections	40%	4.2%	Rising bacterial ear infections, aging population
Dermatological conditions	35%	4.8%	Increasing prevalence of dermatitis and psoriasis
Post-surgical wound infections	15%	3.9%	Steady surgical procedure rates
Others	10%	4.7%	Cosmetic applications

Key Regional Markets

North America and Europe comprise about 65% of the market revenue, driven by high prescription rates for topical antibiotics and corticosteroids. Asia-Pacific presents significant growth potential, expected to expand at a 6% CAGR due to increased healthcare access and rising infectious disease prevalence.

What are the market entry barriers and competitive dynamics?

Regulatory Challenges

• Lack of ongoing pivotal trials limits approval prospects outside existing markets.
• Countries like the US require demonstration of both safety and significant advantages over existing treatments, which existing data do not fully support.

Competition

The combination faces competition from:

• Single-agent antibiotics and corticosteroids formulations with established efficacy.
• Other combination drugs with broader indications, like fluoroquinolone-based ear drops with corticosteroids, some of which are patent-expired.

Patent and Pricing

• Patent protection for specific formulations expired in multiple jurisdictions, leading to increased generic competition.
• Pricing for combination products ranges from USD 20 to USD 50 per course, depending on the formulation.

What are the projections for the next five years?

Market Growth

The combined market for topical ciprofloxacin-based products with corticosteroids is projected to grow at 4.3% CAGR from 2023 to 2028, reaching USD 1.75 billion.

Market Drivers

• Rising bacterial ear infections, especially among aging populations and immunocompromised patients.
• Increasing prevalence of dermatological inflammatory conditions.
• Expansion in emerging markets with improved healthcare infrastructure.

R&D Outlook

• Limited pipeline activity suggests that major pharmaceutical companies prioritize other antibiotics and corticosteroids with broader indications.
• Opportunities persist for repurposing or reformulating existing products to target niche indications or improve delivery mechanisms.

Strategic Recommendations

• Focus on unmet needs for resistant bacterial strains in otic infections.
• Develop formulations with improved bioavailability or reduced side effects to differentiate from generic competition.
• Explore geographic expansion selectively, emphasizing markets with regulatory pathways for existing formulations.

Key Takeaways

• Clinical trial activity for CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE is limited and primarily focused on safety and efficacy in topical applications.
• The market is stable but growing slowly, chiefly driven by otic infections and dermatological needs.
• Patent expirations and generic competition constrain pricing power and market share.
• Future growth hinges on targeted clinical development, expansion to emerging markets, and formulation improvements.

FAQs

1. Are there any recent FDA approvals for CIPROFLOXACIN HYDROCHLORE; HYDROCORTISONE?
No, recent approvals are limited; most jurisdictions rely on older approvals with specific formulations for otic infections.

2. Which indications have the strongest clinical evidence?
Topical treatment of ear infections and inflammatory skin conditions, supported by small-scale clinical trials showing safety and efficacy.

3. What are the main competitors?
Generic ciprofloxacin and hydrocortisone formulations, other combination antibiotics with corticosteroids, and newer agents with broader activity.

4. Is there potential for new indications?
Limited, as no significant pipeline or R&D efforts address expanding indications; most focus remains on existing approved uses.

5. Which markets offer the highest growth potential?
Emerging markets in Asia-Pacific due to increased healthcare access and growing prevalence of infections.

---

References

1. ClinicalTrials.gov. (2023). Search results for ciprofloxacin and hydrocortisone studies.
2. MarketWatch. (2023). Topical antibiotics and corticosteroids market report.
3. IQVIA. (2023). Global pharmaceutical market analysis.
4. FDA. (2022). Approved drug labeling for ciprofloxacin formulations.
5. Statista. (2023). Regional market share data for topical dermatology and otic products.